{"id":4670,"date":"2026-09-04T13:00:00","date_gmt":"2026-09-04T13:00:00","guid":{"rendered":"https:\/\/futurenews24.com\/index.php\/2026\/09\/04\/biotech-deals-august2026\/"},"modified":"2026-09-04T13:59:03","modified_gmt":"2026-09-04T13:59:03","slug":"biotech-deals-august2026","status":"publish","type":"post","link":"https:\/\/futurenews24.com\/index.php\/2026\/09\/04\/biotech-deals-august2026\/","title":{"rendered":"Prime biotech offers in August 2026"},"content":{"rendered":"<p><br \/>\n<\/p>\n<div>\n<p class=\"wp-block-paragraph\">August wasn\u2019t the busiest month for biopharmas and life science firms on the offers entrance, however it did see sustained analysis collaboration in oncology and metabolic illness. As per normal, American firms had been essentially the most keen dealmakers, adopted by biotechs situated within the Asia Pacific area.\u00a0<\/p>\n<div class=\"flourish-embed flourish-bubble-chart\" data-src=\"https:\/\/www.labiotech.eu\/trends-news\/biotech-deals-august2026\/visualisation\/30145099\"><img decoding=\"async\" src=\"https:\/\/public.flourish.studio\/visualisation\/30145099\/thumbnail\" width=\"100%\" alt=\"bubble-chart visualization\"\/><\/div>\n<h2 id=\"h-top-biotech-m-amp-as-of-august-2026\" class=\"wp-block-heading\">Prime biotech M&amp;As of August 2026\u00a0<\/h2>\n<p class=\"wp-block-paragraph\">Regardless of the vacation season, August noticed a gentle move of offers within the biopharma house. The highest acquisition was Lilly\u2019s buyout of Massachusetts-based Merida Biosciences value as much as $2.875 billion. Merida has a pipeline of engineered proteins that targets the antibodies that drive autoimmune and allergic ailments. The lead candidate is a fusion protein for Graves\u2019 illness and thyroid eye illness, each autoimmune situations that have an effect on the thyroid gland. This comes a month after Lilly purchased the psychological well being therapeutics firm AtaiBeckley for $3.8 billion.\u00a0<\/p>\n<p class=\"wp-block-paragraph\">Subsequent, Irish firm Jazz Prescription drugs acquired California-based Actio Biosciences for $820 million upfront and as much as $500 million in milestones. The small molecule developer\u2019s primary candidate is an ion channel inhibitor designed to deal with epilepsy, a neurological dysfunction. Jazz beforehand joined fingers with AbCellera over antibody growth in June.\u00a0<\/p>\n<p class=\"wp-block-paragraph\">In the meantime, California-based Tarsus Prescription drugs has taken over Alkeus Prescription drugs, a developer of therapies for eye situations. Tarsus will spend $450 million upfront and as much as $350 million in milestones and achieve management of Alkeus\u2019 part 2 small molecule for Stargardt illness, an eye fixed illness that causes imaginative and prescient loss. Tarsus is a savant within the discipline, having marketed its eye drops Xdemvy for demodex blepharitis, an inflammatory situation attributable to mites in eyelash follicles and oil glands.\u00a0<\/p>\n<p class=\"wp-block-paragraph\">In a $435 million acquisition, Copenhagen-headquartered LEO Pharma has purchased Tanabe Pharma\u2019s small molecule. Dersimelagon, the oral melanocortin 1 receptor (MC1R) agonist in query, has accomplished part 3 trials for erythropoietic protoporphyria (EPP) and X-linked proto-porphyria (XLP), and the Osaka-based biotech has already filed for U.S. Meals and Drug Administration (FDA) approval. Each EPP and XLP are genetic issues linked to hypersensitivity to daylight. If greenlit by regulators, LEO Pharma will run dersimelagon\u2019s commercialization. The multinational pharma received concerned within the genetics house after it purchased Replay\u2019s gene therapies pipeline in April.\u00a0<\/p>\n<p class=\"wp-block-paragraph\">Additional, Massachusetts-based Werewolf Therapeutics has merged with Ambros Therapeutics, a ache remedy developer situated in California. The latter\u2019s prime candidate is neridronate, a small molecule in part 3 research for ache syndrome sort 1 (CRPS-1), a neuroinflammatory situation that causes extreme and lasting ache following trauma to the bone or an harm. The merger\u2019s monetary phrases had been undisclosed, however Ambros revealed that it additionally gathered $150 million from a non-public placement final month.\u00a0<\/p>\n<p class=\"wp-block-paragraph\">Lastly, Massachusetts-based Fulcrum Therapeutics merged with North Carolina-based Slate Medicines. Whereas the monetary phrases weren&#8217;t revealed, Slate did announce that it gained $245 million from a non-public placement. The merged entity will function as Slate Medicines and deal with growing Slate\u2019s lead candidate SLTE-1009, a monoclonal antibody within the part 1 stage to stop migraines and different headache issues.\u00a0<\/p>\n<div class=\"flourish-embed flourish-chart\" data-src=\"https:\/\/www.labiotech.eu\/trends-news\/biotech-deals-august2026\/visualisation\/30145293\"><img decoding=\"async\" src=\"https:\/\/public.flourish.studio\/visualisation\/30145293\/thumbnail\" width=\"100%\" alt=\"chart visualization\"\/><\/div>\n<h2 id=\"h-biotech-deals-by-approach-in-june-2026\" class=\"wp-block-heading\">Biotech offers by strategy in June 2026\u00a0<\/h2>\n<h3 id=\"h-adcs-advance-in-the-clinic\" class=\"wp-block-heading\">ADCs advance within the clinic\u00a0<\/h3>\n<p class=\"wp-block-paragraph\">In a billion-dollar deal, Roche-owned American multinational Genentech has teamed up with Shanghai-based DualityBio to develop antibody-drug conjugates (ADCs) utilizing the latter\u2019s DUPAC platform. The Chinese language biotech will uncover the ADCs after which take them by part 1a research. Then, Genentech will oversee additional scientific growth and potential commercialization. DualityBio will safe $45 million and is eligible to rake in additional than $1 billion. Genentech\u2019s second deal final month, it beforehand tapped Cambridge-headquartered Astex Prescription drugs to determine small molecules for breast most cancers two months in the past.\u00a0\u00a0<\/p>\n<p class=\"wp-block-paragraph\">Illinois-based Pathos AI has struck a cope with Alphamab Biopharmaceuticals over the latter\u2019s TROP2\/HER3 bispecific antibody-drug conjugate JSKN016 for most cancers. The Jiangsu-located biotech has granted Pathos AI the rights to analysis, develop, manufacture, and commercialize the candidate in areas exterior China, Hong Kong, Macau, and Taiwan.\u00a0 Alphamab is entitled to $125 million upfront and as much as $2.093 billion in growth and commercialization milestones.\u00a0<\/p>\n<div class=\"flourish-embed flourish-chart\" data-src=\"https:\/\/www.labiotech.eu\/trends-news\/biotech-deals-august2026\/visualisation\/30145221\"><img decoding=\"async\" src=\"https:\/\/public.flourish.studio\/visualisation\/30145221\/thumbnail\" width=\"100%\" alt=\"chart visualization\"\/><\/div>\n<h3 id=\"h-collaborations-continue-over-antibodies-small-molecules-and-protacs\" class=\"wp-block-heading\">Collaborations proceed over antibodies, small molecules, and PROTACs\u00a0\u00a0<\/h3>\n<p class=\"wp-block-paragraph\">Genentech\u2019s second deal in August was over a peptide remedy. It knocked on Seoul-based Hanmi Pharm\u2019s door to license the latter\u2019s candidate HM17321 for weight problems, sort 2 diabetes, and coronary heart ailments. Hanmi will proceed growing it in part 1 trials after which will hand the drug over to Genentech, besides in South Korea. HM17321 is first-in-class and is supposed to protect lean physique mass, not like different weight reduction medicine available on the market. Hanmi will scoop up $190 million upfront as a part of a pact value as much as $2.3 billion.\u00a0<\/p>\n<p class=\"wp-block-paragraph\">Japanese firm Ono Pharmaceutical is partnering with Massachusetts-based Mediar Therapeutics, which is growing therapies for fibrosis. The Osaka-located firm has secured an possibility for the worldwide rights to develop and commercialize new medicine to deal with fibrotic ailments which might be focused on the myofibroblast cells, which drive fibrosis.\u00a0 Ono can pay Mediar an upfront payment however didn&#8217;t disclose how a lot.\u00a0\u00a0<\/p>\n<p class=\"wp-block-paragraph\">Furthermore, SK Biopharmaceuticals, headquartered in Seongnam-si, has cast an settlement with Connecticut-based Biohaven for the American biotech\u2019s Kv7 ion channel platform in addition to the epilepsy candidate opakalim. The South Korean firm has nabbed the rights to the platform, and each the businesses will develop the oral potassium channel activator that&#8217;s at present in part 2\/3 trials. Biohaven will rake in as much as $795 million in upfront and milestone funds.\u00a0\u00a0<\/p>\n<p class=\"wp-block-paragraph\">One other deal within the ion channel house, pharma big Lilly is collaborating with California-based OmniAb to find and develop new therapies born from OmniAb\u2019s know-how platform. The American antibody developer can garner as much as $370 million in milestone funds on prime of an undisclosed upfront cost.\u00a0<\/p>\n<p class=\"wp-block-paragraph\">Lastly, Pathos AI\u2019s second pact final month was with British big AstraZeneca. The 2 will develop AstraZeneca\u2019s preclinical candidate AZD4241, a proteolysis-targeting chimeras (PROTACs) designed to focus on breast most cancers that&#8217;s estrogen receptor-positive and human epidermal progress issue receptor 2-negative (ER+\/HER2-). When AZD4241 hits the clinic, Pathos will lead the trials. The monetary phrases of the deal weren&#8217;t revealed. The large pharma was on a roll signing licensing offers within the small molecule and RNA interference areas to deal with most cancers, respiration issues, and kidney ailments with Chinese language firms again in July.\u00a0<\/p>\n<div class=\"flourish-embed flourish-chart\" data-src=\"https:\/\/www.labiotech.eu\/trends-news\/biotech-deals-august2026\/visualisation\/30145159\"><img decoding=\"async\" src=\"https:\/\/public.flourish.studio\/visualisation\/30145159\/thumbnail\" width=\"100%\" alt=\"chart visualization\"\/><\/div>\n<div class=\"flourish-embed flourish-chart\" data-src=\"https:\/\/www.labiotech.eu\/trends-news\/biotech-deals-august2026\/visualisation\/30145199\"><img decoding=\"async\" src=\"https:\/\/public.flourish.studio\/visualisation\/30145199\/thumbnail\" width=\"100%\" alt=\"chart visualization\"\/><\/div>\n<\/div>\n<p><br \/>\n<br \/><a href=\"https:\/\/www.labiotech.eu\/trends-news\/biotech-deals-august2026\/\">Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>August wasn\u2019t the busiest month for biopharmas and life science firms on the offers entrance, however it did see sustained analysis collaboration in oncology and metabolic illness. As per normal, American firms had been essentially the most keen dealmakers, adopted by biotechs situated within the Asia Pacific area.\u00a0 Prime biotech M&amp;As of August 2026\u00a0 Regardless [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4672,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"fifu_image_url":"https:\/\/www.labiotech.eu\/wp-content\/uploads\/2026\/09\/biotech-deals-august.jpg","fifu_image_alt":"","jnews-multi-image_gallery":[],"jnews_single_post":[],"jnews_primary_category":[],"jnews_override_bookmark_settings":[],"jnews_social_meta":[],"jnews_override_counter":[],"footnotes":""},"categories":[10],"tags":[4347,995,847,1220],"class_list":["post-4670","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biotechnology","tag-august","tag-biotech","tag-deals","tag-top"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Prime biotech offers in August 2026 - Future News 24<\/title>\n<meta name=\"description\" content=\"Not a lot went down on the biotech deals front in August 2026, but it did see sustained collaboration in oncology and metabolic disease.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/futurenews24.com\/index.php\/2026\/09\/04\/biotech-deals-august2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Prime biotech offers in August 2026 - Future News 24\" \/>\n<meta property=\"og:description\" content=\"Not a lot went down on the biotech deals front in August 2026, but it did see sustained collaboration in oncology and metabolic disease.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/futurenews24.com\/index.php\/2026\/09\/04\/biotech-deals-august2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Future News 24\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-04T13:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-04T13:59:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.labiotech.eu\/wp-content\/uploads\/2026\/09\/biotech-deals-august.jpg\" \/>\n<meta name=\"author\" content=\"Future News 24\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/www.labiotech.eu\/wp-content\/uploads\/2026\/09\/biotech-deals-august.jpg\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Future News 24\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/09\\\/04\\\/biotech-deals-august2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/09\\\/04\\\/biotech-deals-august2026\\\/\"},\"author\":{\"name\":\"Future News 24\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#\\\/schema\\\/person\\\/cecad1bde21cfc357cf70128144d6c83\"},\"headline\":\"Prime biotech offers in August 2026\",\"datePublished\":\"2026-09-04T13:00:00+00:00\",\"dateModified\":\"2026-09-04T13:59:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/09\\\/04\\\/biotech-deals-august2026\\\/\"},\"wordCount\":1063,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/09\\\/04\\\/biotech-deals-august2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.labiotech.eu\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/biotech-deals-august.jpg\",\"keywords\":[\"August\",\"biotech\",\"deals\",\"top\"],\"articleSection\":[\"BioTechnology\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/09\\\/04\\\/biotech-deals-august2026\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/09\\\/04\\\/biotech-deals-august2026\\\/\",\"url\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/09\\\/04\\\/biotech-deals-august2026\\\/\",\"name\":\"Prime biotech offers in August 2026 - Future News 24\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/09\\\/04\\\/biotech-deals-august2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/09\\\/04\\\/biotech-deals-august2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.labiotech.eu\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/biotech-deals-august.jpg\",\"datePublished\":\"2026-09-04T13:00:00+00:00\",\"dateModified\":\"2026-09-04T13:59:03+00:00\",\"description\":\"Not a lot went down on the biotech deals front in August 2026, but it did see sustained collaboration in oncology and metabolic disease.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/09\\\/04\\\/biotech-deals-august2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/09\\\/04\\\/biotech-deals-august2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/09\\\/04\\\/biotech-deals-august2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.labiotech.eu\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/biotech-deals-august.jpg\",\"contentUrl\":\"https:\\\/\\\/www.labiotech.eu\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/biotech-deals-august.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/2026\\\/09\\\/04\\\/biotech-deals-august2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/futurenews24.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Prime biotech offers in August 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#website\",\"url\":\"https:\\\/\\\/futurenews24.com\\\/\",\"name\":\"Future News 24\",\"description\":\"The Smart Hub for AI and Next-Gen Innovation\",\"publisher\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/futurenews24.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#organization\",\"name\":\"Future News 24\",\"url\":\"https:\\\/\\\/futurenews24.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/futurenews24.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/fn24-favicon.png\",\"contentUrl\":\"https:\\\/\\\/futurenews24.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/fn24-favicon.png\",\"width\":250,\"height\":250,\"caption\":\"Future News 24\"},\"image\":{\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/futurenews24.com\\\/#\\\/schema\\\/person\\\/cecad1bde21cfc357cf70128144d6c83\",\"name\":\"Future News 24\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d57f07142d73cb5503ab2446ea7bc9ef3d0a5ba378d64a6157692311e42bf097?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d57f07142d73cb5503ab2446ea7bc9ef3d0a5ba378d64a6157692311e42bf097?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/d57f07142d73cb5503ab2446ea7bc9ef3d0a5ba378d64a6157692311e42bf097?s=96&d=mm&r=g\",\"caption\":\"Future News 24\"},\"sameAs\":[\"https:\\\/\\\/futurenews24.com\"],\"url\":\"https:\\\/\\\/futurenews24.com\\\/index.php\\\/author\\\/mridulpahuja20\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Prime biotech offers in August 2026 - Future News 24","description":"Not a lot went down on the biotech deals front in August 2026, but it did see sustained collaboration in oncology and metabolic disease.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/futurenews24.com\/index.php\/2026\/09\/04\/biotech-deals-august2026\/","og_locale":"en_US","og_type":"article","og_title":"Prime biotech offers in August 2026 - Future News 24","og_description":"Not a lot went down on the biotech deals front in August 2026, but it did see sustained collaboration in oncology and metabolic disease.","og_url":"https:\/\/futurenews24.com\/index.php\/2026\/09\/04\/biotech-deals-august2026\/","og_site_name":"Future News 24","article_published_time":"2026-09-04T13:00:00+00:00","article_modified_time":"2026-09-04T13:59:03+00:00","og_image":[{"url":"https:\/\/www.labiotech.eu\/wp-content\/uploads\/2026\/09\/biotech-deals-august.jpg","type":"","width":"","height":""}],"author":"Future News 24","twitter_card":"summary_large_image","twitter_image":"https:\/\/www.labiotech.eu\/wp-content\/uploads\/2026\/09\/biotech-deals-august.jpg","twitter_misc":{"Written by":"Future News 24","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/futurenews24.com\/index.php\/2026\/09\/04\/biotech-deals-august2026\/#article","isPartOf":{"@id":"https:\/\/futurenews24.com\/index.php\/2026\/09\/04\/biotech-deals-august2026\/"},"author":{"name":"Future News 24","@id":"https:\/\/futurenews24.com\/#\/schema\/person\/cecad1bde21cfc357cf70128144d6c83"},"headline":"Prime biotech offers in August 2026","datePublished":"2026-09-04T13:00:00+00:00","dateModified":"2026-09-04T13:59:03+00:00","mainEntityOfPage":{"@id":"https:\/\/futurenews24.com\/index.php\/2026\/09\/04\/biotech-deals-august2026\/"},"wordCount":1063,"commentCount":0,"publisher":{"@id":"https:\/\/futurenews24.com\/#organization"},"image":{"@id":"https:\/\/futurenews24.com\/index.php\/2026\/09\/04\/biotech-deals-august2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.labiotech.eu\/wp-content\/uploads\/2026\/09\/biotech-deals-august.jpg","keywords":["August","biotech","deals","top"],"articleSection":["BioTechnology"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/futurenews24.com\/index.php\/2026\/09\/04\/biotech-deals-august2026\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/futurenews24.com\/index.php\/2026\/09\/04\/biotech-deals-august2026\/","url":"https:\/\/futurenews24.com\/index.php\/2026\/09\/04\/biotech-deals-august2026\/","name":"Prime biotech offers in August 2026 - Future News 24","isPartOf":{"@id":"https:\/\/futurenews24.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/futurenews24.com\/index.php\/2026\/09\/04\/biotech-deals-august2026\/#primaryimage"},"image":{"@id":"https:\/\/futurenews24.com\/index.php\/2026\/09\/04\/biotech-deals-august2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.labiotech.eu\/wp-content\/uploads\/2026\/09\/biotech-deals-august.jpg","datePublished":"2026-09-04T13:00:00+00:00","dateModified":"2026-09-04T13:59:03+00:00","description":"Not a lot went down on the biotech deals front in August 2026, but it did see sustained collaboration in oncology and metabolic disease.","breadcrumb":{"@id":"https:\/\/futurenews24.com\/index.php\/2026\/09\/04\/biotech-deals-august2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/futurenews24.com\/index.php\/2026\/09\/04\/biotech-deals-august2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/futurenews24.com\/index.php\/2026\/09\/04\/biotech-deals-august2026\/#primaryimage","url":"https:\/\/www.labiotech.eu\/wp-content\/uploads\/2026\/09\/biotech-deals-august.jpg","contentUrl":"https:\/\/www.labiotech.eu\/wp-content\/uploads\/2026\/09\/biotech-deals-august.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/futurenews24.com\/index.php\/2026\/09\/04\/biotech-deals-august2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/futurenews24.com\/"},{"@type":"ListItem","position":2,"name":"Prime biotech offers in August 2026"}]},{"@type":"WebSite","@id":"https:\/\/futurenews24.com\/#website","url":"https:\/\/futurenews24.com\/","name":"Future News 24","description":"The Smart Hub for AI and Next-Gen Innovation","publisher":{"@id":"https:\/\/futurenews24.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/futurenews24.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/futurenews24.com\/#organization","name":"Future News 24","url":"https:\/\/futurenews24.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/futurenews24.com\/#\/schema\/logo\/image\/","url":"https:\/\/futurenews24.com\/wp-content\/uploads\/2026\/06\/fn24-favicon.png","contentUrl":"https:\/\/futurenews24.com\/wp-content\/uploads\/2026\/06\/fn24-favicon.png","width":250,"height":250,"caption":"Future News 24"},"image":{"@id":"https:\/\/futurenews24.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/futurenews24.com\/#\/schema\/person\/cecad1bde21cfc357cf70128144d6c83","name":"Future News 24","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/d57f07142d73cb5503ab2446ea7bc9ef3d0a5ba378d64a6157692311e42bf097?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/d57f07142d73cb5503ab2446ea7bc9ef3d0a5ba378d64a6157692311e42bf097?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d57f07142d73cb5503ab2446ea7bc9ef3d0a5ba378d64a6157692311e42bf097?s=96&d=mm&r=g","caption":"Future News 24"},"sameAs":["https:\/\/futurenews24.com"],"url":"https:\/\/futurenews24.com\/index.php\/author\/mridulpahuja20\/"}]}},"_links":{"self":[{"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/posts\/4670","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/comments?post=4670"}],"version-history":[{"count":1,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/posts\/4670\/revisions"}],"predecessor-version":[{"id":4671,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/posts\/4670\/revisions\/4671"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/media\/4672"}],"wp:attachment":[{"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/media?parent=4670"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/categories?post=4670"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/futurenews24.com\/index.php\/wp-json\/wp\/v2\/tags?post=4670"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}